Description
The C15 monoclonal antibody specifically recognizes the variable alpha 24 region of the α subunit of the human αβ T cell receptor for antigen (TCR Vα24). TCR Vα24 combines with joining region 18 (Jα18) to form Vα24-Jα18 (Arden nomenclature, or TRAV10-TRAJ18 in the IMGT nomenclature). TCR Vα24 can pair with different TCR Vβ region containing TCR β chains. The paired expression of TCR Vα24 with semivariant TCR Vβ11 identifies CD3+TCR αβ+ positive thymocytes and from ~ 0.01-0.92% of peripheral blood CD3+ TCR αβ+ T cells known as invariant NKT (iNKT) cells or Type I NKT cells. iNKT cells can be divided into three subpopulations which are either CD4+, CD8+, or CD4-CD8- double negative. Due to their innate-like responsiveness, tissue resident iNKT cells are capable of rapid effector responses to microbial or self-lipid antigens presented by the cell surface MHC class Ib molecule, CD1d. iNKT cells recognize and respond to α-galactosylceramide (α-GalCer) and various self-lipids such as sphingolipids and diacylglycerols and microbial lipids presented by CD1d. iNKT cells can produce high levels of cytokines, including IL-4 and IFN-γ, and act as cytotoxic T cells against CD1d+ target cells following stimulation. The C15 antibody is useful for multiparameter analyses designed to study the nature of TCR Vα24-positive T cells and T cell clones. When combined with other TCR V region-specific antibodies, C15 is helpful for characterizing TCR Vα repertoires expressed by T cell populations collected from blood, tissues or other sources in health and disease models including inflammation, infectious diseases, autoimmunity, and tumors. The C15 antibody reportedly stimulates the proliferation of TCR Vα24-positive T cells.
BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application. For optimal and reproducible results, BD Horizon Brilliant™ Stain Buffer should be used anytime BD Horizon Brilliant dyes are used in a multicolor flow cytometry panel. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. When BD Horizon Brilliant Stain Buffer is used in in the multicolor panel, it should also be used in the corresponding compensation controls for all dyes to achieve the most accurate compensation. For the most accurate compensation, compensation controls created with either cells or beads should be exposed to BD Horizon Brilliant Stain Buffer for the same length of time as the corresponding multicolor panel. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
2. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
3. For U.S. patents that may apply, see bd.com/patents.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
6. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
7. Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
8. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
9. An isotype control should be used at the same concentration as the antibody of interest.
